Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM1 in Parkinson's Disease With Motor Fluctuations
NCT07585565Phase 2Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- May 2026
- Primary completion
- Mar 2028
- Modality
- Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of monosialotetrahexosylganglioside in Parkinson's disease (PD), sponsored by Qilu Pharmaceutical. Planned start May 2026; status: not yet recruiting.
02
Drugs
monosialotetrahexosylganglioside
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07585565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07585565.